<DOC>
	<DOCNO>NCT00006488</DOCNO>
	<brief_summary>Parkinson 's disease characterize loss neuron produce dopamine region brain call substantia nigra . In early stage disease , disease respond agent replace dopamine levodopa . Patients advanced disease wide fluctuation response levodopa , exhibit period . This due continue degeneration neuron . Recombinant-methionyl human glial cell line-derived neurotrophic factor ( r-metHuGDNF GDNF ) neurotrophic factor promotes survival dopaminergic neuron . This protein produce recombinant technology almost identical naturally produce factor . Results animal study indicate GDNF potential benefit patient advance Parkinson 's disease . The purpose clinical trial determine whether GDNF work relieve symptom advance Parkinson 's disease . The study also test delivery GDNF use catheter implant putamen , area brain associate Parkinson 's disease , infusion pump implant skin abdomen chest . GDNF place pump deliver catheter brain . The purpose study determine potential benefit side effect GDNF . The performance safety catheter/infusion pump system also assess . The study last 6 month . Subjects undergo neurological testing , computerized gait assessment neurological imaging .</brief_summary>
	<brief_title>Continuously Infused Intracerebral ( IC ) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor ( r-metHuGDNF ) Treatment Idiopathic Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Patients advance idiopathic Parkinson 's disease treat optimal dos levodopa , dopamine agonist , catecholomethyl transferase ( COMT ) inhibitor , selegiline 2 month prior implantation intracerebral catheter pump . Must able undergo surgery require implant pump catheter . Must capable informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2004</verification_date>
</DOC>